Enroflon®
Foaming tablets for intrauterine administration
Specification
Enrofloxacin is a fluoroquinolone derivative. It inhibits DNA gyrase,
growth and division of bacteria. The antibiotic has a bactericidal
effect on gram-negative bacteria at the stage of division, and resting
and on gram-positive – at the stage of division. Enrofloxacin has
broad-spectrum antibacterial activity against gram-positive and
gram-negative bacteria, including E. coli, Haemophilus spp., Klebsiella
spp., Pasteurella spp., Pseudomonas spp., Bordetella spp., Campylobacter
spp., Erysipelothris spp., Corynebacterium spp., Staphylococcus spp.,
Streptococcus spp., Actinobacillus spp., Clostridium spp., Bacteroides spp.,
Fusobacterium spp. and Mycoplasma spp. The resistance of bacteria to
Enroflon® foaming tablets develops relatively slowly.
Due to the foaming, the drug is equally distributed along the
endometrial mucosa. Produced carbon dioxide enhances enrofloxacin
resorption and contributes to its penetration into deeper layers of the
endometrium. Enrofloxacin is partially metabolized to ciprofloxacin
in the liver. Fluoroquinolones are mainly excreted in the urine and
bile.
Indications
Enroflon® foaming tablets is used for treatment and prevention of inflammation in the uterus after obstetrics, expulsion of the placenta, abortions, complicated and pathological delivery, acute postpartum endometritis in cattle and pigs.
Composition
1 tablet contains 0.36 g of enrofloxacin.
Dosage
For prevention, one tablet is administered once immediately after expulsion of the placenta, abortion or complicated and pathological delivery.
For treatment, 2-4 tablets are administered 2-3 times with a 24-hour interval until clinical recovery.